CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Core Insights - CorMedix Inc. will report its financial results for Q1 2025 on May 6, 2025, before market opens [1] - The company will host a corporate update conference call at 8:30 AM ET on the same day [2] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [2] - The company's lead product, DefenCath® (taurolidine and heparin), received FDA approval on November 15, 2023 [2] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [2] - CorMedix plans to commence clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 [2] - The company also intends to develop DefenCath as a catheter lock solution for other patient populations [2]